Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.10.0.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues $ 2,500 $ 2,500 $ 257,500 $ 7,500
Operating expenses:        
Research and development expenses 897,098 1,383,863 3,081,319 6,871,028
General and administrative expenses 1,188,076 1,206,510 3,630,822 4,174,583
Total operating expenses 2,085,174 2,590,373 6,712,141 11,045,611
Operating loss (2,082,674) (2,587,873) (6,454,641) (11,038,111)
Other income (expense):        
Interest income 17,619 18,099 54,882 52,995
Interest expense (1,498) (1,383) (4,190) (155,843)
Change in fair value of derivative instruments 236,270 2,679,770 1,805,319 (403,155)
Fees related to issuance of indcuement warrants and other expenses (242,396) (5,667) (806,115)
Total other income (expense) 252,391 2,454,090 1,850,344 (1,312,118)
Net loss $ (1,830,283) $ (133,783) $ (4,604,297) $ (12,350,229)
Net loss per share - basic (in dollars per share) $ (0.12) $ (0.01) $ (0.30) $ (1)
Net loss per share - diluted (in dollars per share) $ (0.12) $ (0.18) $ (0.30) $ (1)
Weighted average common shares outstanding - basic (in shares) 15,171,495 14,060,844 15,144,425 12,380,054
Weighted average common shares outstanding - diluted (in shares) 15,171,495 14,163,072 15,144,425 12,380,054
Comprehensive loss:        
Net loss $ (1,830,283) $ (133,783) $ (4,604,297) $ (12,350,229)
Foreign currency translation adjustment (512) (1,005) (2,001) (1,560)
Comprehensive loss $ (1,830,795) $ (134,788) $ (4,606,298) $ (12,351,789)